The United Kingdom Thrombotic Thrombocytopenic Purpura Registry (UK TTP Registry)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-31

Study Completion Date

2023-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a UK (United Kingdom) based registry, involving all sites treating newly presenting Thrombotic Thrombocytopenic Purpura (TTP). From this registry, important epidemiological data will be obtained. Admission and remission samples will be collected. DNA will be collected and analysed from patients wishing to participate to determine if any link exists between mutations/polymorphisms and the risk of TTP. As part of NHS commissioning, we will be undertaking long term follow up, to understand the impact of acute TTP on morbidity and mortality.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)

NCT00937131

Thrombotic Thrombocytopenic Purpura (TTP)

COMPLETED PHASE2

Immunological Aspect of Thrombotic Thrombocytopenic Purpura (TTP)

NCT06945861

Thrombotic Thrombocytopenic Purpura (TTP)

RECRUITING

The ConNeCT Study: Neurological Complications of TTP

NCT04981028

Thrombotic Thrombocytopenic Purpura

UNKNOWN

.German TTP-Registry (Thrombotic Thrombocytopenic Purpura)

NCT05389007

Thrombotic Thrombocytopenic Purpura

UNKNOWN

Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura

NCT05046717

Acquired Thrombotic Thrombocytopenic Purpura

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The UK TTP registry started in January 2009, following 3 years MRC funding, involving UK collaboration from all sites treating TTP patients. It has resulted in a cohort of data and samples from UK TTP cases. The registry promotes a collaborative approach with all UK patients and physicians involved with this life threatening disorder. The UK TTP registry has been used to provide information for highly specialist commissioning via NHS England and moving forward will be required to provide data relevant to the UK TTP Group and commissioners.

University College London (UCL) Haemostasis Research Unit (HRU) will collect and collate the data and help administrate for those sites participating in the registry. However, ADAMTS13 assays will no longer be subsidised. For those sites undertaking local assays, a record of cases will be shared centrally. The UK TTP registry will be part of the UK TTP Group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

TTP - Thrombotic Thrombocytopenic Purpura

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ADAMTS13, VWF assay

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a clinical diagnosis of TTP, defined by thrombocytopenia, MAHA which may be associated with clinical evidence of organ compromise.Confirmed by severely reduced ADAMTS13 levels and/or a positive antibody screen.
* No age restriction.
* Consent for addition to the Registry and collection/storage of admission information once in remission.
* Consent to collect, analyse and store EDTA sample once in remission.
* Consent to store samples once in remission (sample taken as part of standard care).
* For sites undertaking ADAMTS13 analysis, consent to send admission and remission samples for analysis relating to TTP.
* Follow up laboratory and clinical data at least yearly to identify any changes.